As of May 25, 2025, Eurogerm SA's estimated intrinsic value ranges from $27.01 to $71.02 per share, depending on the valuation methodology applied.
Valuation Method | Fair Value (USD) | Implied Upside/Downside |
---|---|---|
Discounted Cash Flow (10Y) | $40.23 | -16.5% |
Discounted Cash Flow (5Y) | $32.44 | -32.7% |
Dividend Discount Model (Multi-Stage) | $27.01 | -43.9% |
Dividend Discount Model (Stable) | $71.02 | +47.4% |
Earnings Power Value | $68.88 | +43.0% |
Is Eurogerm SA (ALGEM.PA) undervalued or overvalued?
With the current market price at $48.18, the stock appears to be moderately overvalued.
Intrinsic value represents the "true" worth of a company based on its fundamentals rather than market sentiment. We've employed multiple methodologies to triangulate Eurogerm SA's intrinsic value, including:
The cost of capital is a critical factor in valuation models, representing the required return for investors.
WACC Component | Low | High |
---|---|---|
Long-term bond rate | 2.6% | 3.1% |
Equity market risk premium | 5.2% | 6.2% |
Adjusted beta | 0.56 | 0.75 |
Cost of equity | 5.5% | 8.3% |
Cost of debt | 5.0% | 5.0% |
Tax rate | 26.4% | 26.8% |
Debt/Equity ratio | 0.05 | 0.05 |
After-tax WACC | 5.4% | 8.1% |
Our DCF model projects cash flows over 5-year and 10-year horizons, with the following key assumptions:
DCF Model | Fair Value | Enterprise Value | % from Terminal Value |
---|---|---|---|
5-Year Growth | $32 | $121M | 78.5% |
10-Year Growth | $40 | $154M | 66.5% |
5-Year EBITDA | $28 | $102M | 74.5% |
10-Year EBITDA | $33 | $124M | 58.4% |
The DDM values a company based on its expected future dividend payments. We used two approaches:
EPV assesses a company's value based on its current normalized earnings power, assuming no growth.
EPV Component | Value |
---|---|
Normalized Earnings | $18M |
Discount Rate (WACC) | 8.1% - 5.4% |
Enterprise Value | $223M - $332M |
Net Debt | $(19)M |
Equity Value | $242M - $351M |
Outstanding Shares | 4M |
Fair Value | $56 - $82 |
Selected Fair Value | $68.88 |
Metric | Value |
---|---|
Market Capitalization | $207M |
Enterprise Value | $189M |
Trailing P/E | 16.80 |
Forward P/E | 32.61 |
Trailing EV/EBITDA | 7.50 |
Current Dividend Yield | 141.49% |
Dividend Growth Rate (5Y) | -9.98% |
Debt-to-Equity Ratio | 0.05 |
To determine the most reliable intrinsic value estimate, we weigh each valuation method based on:
Valuation Method | Weight | Weighted Value |
---|---|---|
Discounted Cash Flow (10Y) | 30% | $12.07 |
Discounted Cash Flow (5Y) | 25% | $8.11 |
Dividend Discount Model (Multi-Stage) | 20% | $5.40 |
Dividend Discount Model (Stable) | 15% | $10.65 |
Earnings Power Value | 10% | $6.89 |
Weighted Average | 100% | $43.12 |
Based on our comprehensive valuation analysis, Eurogerm SA's weighted average intrinsic value is $43.12, which is approximately 10.5% below the current market price of $48.18.
Key investment considerations:
Given these factors, we believe Eurogerm SA is currently moderately overvalued with the potential for long-term appreciation based on the company's growth trajectory and financial strength.